Welcome to our dedicated page for Eloxx Pharmaceuticals SEC filings (Ticker: ELOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eloxx Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eloxx Pharmaceuticals's regulatory disclosures and financial reporting.
Eloxx Pharmaceuticals reports a Schedule 13G filing showing Stonepine-affiliated filers beneficially own 403,228 shares of Common Stock, equal to 9.9% of the class. The filing states the position comprises 400,000 shares and pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation. The percentage is calculated using 4,036,314 shares outstanding immediately after the offering, as reported in the issuer's June 9, 2026 prospectus. The reporting persons disclaim group membership and disavow beneficial ownership beyond their pecuniary interest; shared voting and dispositive power are reported for 403,228 shares.
Eloxx Pharmaceuticals reported that certain affiliated investment entities led by Invus and Avicenna hold aggregate beneficial interests in its common stock. As of June 9, 2026, the Reporting Persons beneficially owned 403,586 shares (an aggregate of 400,000 shares and 3,586 warrants) representing 9.99% of issued and outstanding shares. The filing states Invus Public Equities directly held 350,525 shares and 43,816 pre-funded warrants, and Avicenna Fund directly held 49,475 shares and 6,184 pre-funded warrants. Shares outstanding used for the percentage calculation were 4,036,314 as of June 10, 2026. A Beneficial Ownership Limitation prevents exercises that would exceed 9.99%.
Eloxx Pharmaceuticals director Stephen W. Webster received a new stock option grant. On the reported date, he was awarded options to acquire 13,587 shares of Eloxx common stock at an exercise price of $11.00 per share. These options vest in 24 substantially equal monthly installments and will be fully vested on the second anniversary of the grant date, as long as he continues serving the company. Following this grant, Webster holds 13,587 stock options directly under this award, which are scheduled to expire on June 8, 2036.
Eloxx Pharmaceuticals director Alan Edmund Walts received a grant of 8,590 stock options to buy common stock. The options have an exercise price of $11.00 per share and expire on June 8, 2036. They vest in 24 substantially equal monthly installments, becoming fully exercisable on the second anniversary of the grant date, as long as he continues to serve the company. Following this award, he holds 8,590 stock options directly, and the filing does not show any open-market purchases or sales.
Eloxx Pharmaceuticals director Nina S. Kjellson received a grant of stock options covering 13,587 shares of Common Stock. The options have an exercise price of $11.00 per share and expire on June 8, 2036. They vest in 24 substantially equal monthly installments over two years, conditioned on her continued service. Following this grant, she holds 13,587 stock options directly, reflecting a compensation-related award rather than an open-market purchase or sale.
Eloxx Pharmaceuticals, Inc. reported that President and CEO Sumit Aggarwal received a grant of stock options covering 328,833 shares of common stock. These options have an exercise price of $1.65 per share and expire on September 19, 2035.
The options were originally granted on September 19, 2025 and were subject to a performance-based vesting condition that was satisfied on June 10, 2026. Vesting will occur as to 1/36 of the options on July 31, 2026, with the remaining options vesting in equal monthly installments over the following 35 months, contingent on Aggarwal’s continued service.
Eloxx Pharmaceuticals director Steven D. Rubin received a new stock option grant. The award covers 4,018 options to buy Eloxx common stock at an exercise price of $11.00 per share and expires on June 8, 2036.
The option vests in 24 substantially equal monthly installments, becoming fully vested on the second anniversary of the June 8, 2026 grant date, as long as Rubin continues to provide service to the company. After this grant, he holds 4,018 stock options directly.
Eloxx Pharmaceuticals is offering 2,975,000 shares of common stock and pre-funded warrants to purchase up to 3,025,000 shares. The public offering price is $11.00 per share and $10.99 per pre-funded warrant, producing total gross proceeds of $65,969,750 before underwriting discounts. The underwriters expect to deliver the securities on or about June 10, 2026. The prospectus states the offering proceeds to Eloxx, before expenses, are $61,349,750. The offering assumes 461,314 shares outstanding as of May 31, 2026 and concurrent exercises of up to 600,000 shares from existing pre-funded warrants. Pro forma cash and cash equivalents after the offering are presented as $65,713,000.
Domicilium reporting entities filed an amended Schedule 13G/A disclosing beneficial ownership in Eloxx Pharmaceuticals common stock. The amendment reports 23,478 shares (4.9%) held by Domicilium Capital Partners LLC and Daniel Simon, and 9,193 shares (2.0%) held by Domicilium Real Estate Fund III LP/GP. The filing notes an 11-for-1 reverse stock split effective May 29, 2026.
The report states the shares are directly owned by advisory clients of Domicilium Capital Partners LLC and includes a Joint Filing Agreement. Reporting persons disclaim beneficial ownership except for pecuniary interest; signatures are dated 06/05/2026.